I'm LongbridgeAI, I can summarize articles.Radiopharm Theranostics (RADX) closed a US$4.1 million registered direct offering and is pursuing an Australian Placement and Share Purchase Plan to raise approximately A$12.7 million. These funds will support its oncology radiopharmaceutical pipeline, including Phase 3 studies for RAD101 and advancement of other programs. The company remains debt-free but faces analyst concerns regarding persistent losses and cash burn, with technical indicators currently bearish.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
An update from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) is now available.
On July 28, 2026, Radiopharm Theranostics closed a registered direct offering of 1,281,646 American Depositary Shares at US$3.16 per ADS, raising about US$4.1 million before fees from U.S. accredited institutional investors, alongside a concurrent private placement of unregistered warrants exercisable through July 31, 2029. The company is also pursuing an Australian Placement and a Share Purchase Plan that could together add roughly A$12.7 million, with related share and option issuances, including 40 million ordinary shares and one option per new share, subject to shareholder approval at an extraordinary general meeting expected around September 11, 2026.
Under these capital-raising initiatives, Radiopharm plans to fund preparation for its RAD101 registrational Phase 3 study, completion of RAD204 dose escalation, and advancement of RAD202, RAD402 and RV01 therapeutic programs, while supporting strategic partnering and general corporate needs. The multi-pronged financing, spanning U.S. institutional investors and Australian retail and professional investors, is poised to strengthen the company’s balance sheet and accelerate clinical development, potentially enhancing its positioning in the competitive radiopharmaceutical oncology space.
The most recent analyst rating on (RADX) stock is a Buy
with a $16.00 price target.
To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock,
see the RADX Stock Forecast page.
Spark’s Take on RADX Stock
According to Spark, TipRanks’ AI Analyst, RADX is a Neutral.
The score is held down primarily by persistent losses and ongoing cash burn, despite a debt-free balance sheet. Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation support is limited because the company is unprofitable (negative P/E) and offers no dividend yield.
To see Spark’s full report on RADX stock,
click here.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic use in areas of high unmet medical need. Listed on the ASX and Nasdaq, it is building a diversified pipeline of peptide, small-molecule and monoclonal antibody-based radiotherapeutics, with ongoing Phase 1 and Phase 2 trials across solid tumor indications including lung, breast and brain metastases.
Average Trading Volume: 61,607
Technical Sentiment Signal: Sell
Current Market Cap: $47.07M
Learn more about RADX stock on TipRanks’ Stock Analysis page.